SCHEMBL4627487

SCHEMBL4627487

NC(=Nc1ccc(OCc2ccccc2)cc1)NC(=O)c1cc(Cl)ccc1Cl

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SCN2A Q99250 2/20 0.61
▸ SCN5A Q14524 1/20 0.56
▸ NOS3 P29474 2/20 0.47
▸ NOS1 P29475 2/20 0.47
▸ NOS2 P35228 2/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ NPC1 O15118 4/20 0.46
▸ RAB9A P51151 4/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ POLB P06746 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ AR P10275 1/20 0.46
▸ MAOB P27338 1/20 0.46
▸ SMO Q99835 1/20 0.45
▸ RXRA P19793 1/20 0.45
▸ RXRB P28702 1/20 0.45
▸ RXRG P48443 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4627497 0.89 SCN2A (0.66) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4629225 0.85 SCN2A (0.80) SCN2ASCN5AMEN1KMT2ANPC1
SCHEMBL4628983 0.84 SCN2A (0.62) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4628715 0.84 SCN2A (0.72) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4628807 0.83 SCN2A (0.66) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4628694 0.81 SCN2A (0.84) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4629268 0.79 SCN2A (0.64) SCN2ASCN5ANOS3NOS1NOS2
SCHEMBL4627483 0.78 TAS1R3 (0.56) MEN1KMT2ANPC1RAB9ASMN1; SMN2
SCHEMBL4629368 0.78 SCN2A (0.59) SCN2ANOS3NOS1NOS2NPC1
SCHEMBL4628743 0.77 SCN2A (0.67) SCN2ANOS3NOS1NOS2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 — — EP claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 — — EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 — — EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 — — US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SCN2A 1613/4885SCN5A 1196/4885NOS3 3254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback